ALK and non-small cell lung carcinoma: Nowadays, with the recognition of EGFR and KRAS gene mutations, MET amplification and EML4-ALK rearrangements, new therapies directed against defined molecular targets profoundly impact on the non-small cell lung cancer (NSCLC) [1].